890898P
Avanti
DOTMA
Avanti Research™ - A Croda Brand
别名:
1,2-二-O-十八烯酰-3-三甲铵丙烷（氯化盐）
方案
>99% (TLC)
表单
powder
包装
pkg of 2 × 100 mg (890898P-200mg)
pkg of 1 × 25 mg (890898P-25mg)
制造商/商品名称
Avanti Research™ - A Croda Brand
应用
advanced drug delivery
脂质类型
cationic lipids
transfection
运输
dry ice
储存温度
−20°C
SMILES字符串
[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]
InChI key
LDGWQMRUWMSZIU-LQDDAWAPSA-M
正在寻找类似产品? 访问 产品对比指南
应用
DOTMA适合作为miRNA递送系统的结构单元并用于制备。
生化/生理作用
DOTMA是一种阳离子脂质，可用作基因治疗的非病毒载体。它对体外和体内基因转染均有作用。DOTMA可使脂质体带上正电荷，因此促成更高效的脂质体-细胞膜相互作用。
包装
5 mL透明玻璃密封安瓿瓶(890898P-200mg)
5 mL透明玻璃密封安瓿瓶(890898P-25mg)
法律信息
Avanti Research is a trademark of Avanti Polar Lipids, LLC
储存分类代码
11 - Combustible Solids
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持